Table 5.
Literature review of LESS procedure in EC survival.
| Authors | Year | Type of study | No. of cases | FIGO stage | Median lymph nodes (n) | Oncological outcomes | |||
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | DOD | Median follow-up (month) | Ovrall survival | ||||||
| Corrado G (22) | 2016 | R | 50 | I-IIIA | 14(5-20) | 0 | 0 | 36 m (16-62) |
NR |
| Barnes H (11) | 2017 | R | 110 | I-IV | 30 PL(2-40), 15 PAO(1-29) |
6 (5.4%) |
2 (1.8%) |
9.9m | |
| Chambers LM (4) | 2019 | R | 284 | IA-IVB | NR | 31.1m (0.5-86.3) | 5 years PFS: 85.2%, 5 years OS: 91.8%; |
||
| Our study | 2023 | R | 78 | I-IV | 23 PL(16-28) 2 PAO (0-6) |
5(6.41%) | 1(1.28%) | 45m (20-66) | |
R, Retrospective; DOD, Dead of disease; NR, No reported; PL, Pelvic lymph nodes; PAO, Para-aortic lymph nodes.